Salmonella vectored vaccines against Chlamydia and methods of use
US8703153B2 · kind B2 · utility
17Cited by
28References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 16, 2009 |
| Grant date | Apr 22, 2014 |
| Priority date | — |
| Expiry date | Jun 16, 2029 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides an attenuated Salmonella vaccine vector comprising one or more heterologous polynucleotides that encode immunogenic Chlamydial peptides. In one embodiment, the attenuated Salmonella vaccine vector comprises aroC and ssaV attenuating mutations. The heterologous polynucleotides encoding the immunogenic Chlamydial peptides can be under the control of an inducible promoter such as a Salmonella ssaG promoter. In one embodiment of the invention, the immunogenic Chlamydial peptide is a PmpG peptide, for instance, a CT110, CT84 or CT40 peptide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.